focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
you are probably right in terms of still trying to find optimum schedule and so on... but i doubt the MHRA would give them carte blanche for dosing. They must surely have an agreed dosing schedule/plan.
Ultimately what I was trying to understand is how many more doses might the "partial response" patient expect to receive and from that maybe do some back of a fag packet extrapolation. the result we are all obviously hoping for would be complete tumour removal!
On another note though, I would imagine in certain indications, a "partial response" alone may be sufficient to make an inoperable tumour, operable. A "partial" response could add years onto a patient prognosis.
"All three patients in Cohort 2 successfully received two doses and the injections were well tolerated with no safety concerns, Scancell said, while all three showed a delayed-type hypersensitivity response to the vaccine, which is indicative of a T cell response,"
wonder if they will ever finish this sentence.
I have tried to look up the information from the trials website, but can't seem to see it there or in the presentation pdf from trinity delta - what is the dosing schedule for the trial? How many doses of the medication would each patient expect to receive over what time period? It would be useful to put today's very early results into context if we knew how early in the treatment regimen that patient is.
"Under the terms of the agreement, Genmab MADE an UPFRONT payment to Scancell and the Company is eligible TO RECEIVE milestone payments of up to $208 million for each product developed and commercialised, up to a maximum of $624 million if Genmab develops and commercialises products across all defined modalities."
To me the highlighted words describe that the Upfront payments are NOT a part payment of the Milestone payments. The upfront payment has been made and in addition to that, they can receive £208 million per product.
@chester I'm fairly sure it's not MHRA approval needed. The MHRA approves the whole trial before it begins. The approval required is from the clinical oversight panel. This is just an independent group of clinicians, appointed by the trial, to oversee the data coming out of the trial and advise the sponsor of any safety concerns.
Burble could probably confirm - or correct me.
Thanks Berm - interesting food for thought there. I don't disagree with a lot of what you say, and agree that the NASDAQ in itself is not a panacea. However, I do think we are being massively held back by being traded on this market. Yesterday's news was imo a monumental step forward for the company, but to this market it was seen as nothing more than an opportunity to trade. Congrats to those people who made their quick 20% - but that doesn't help us long term investors. On the balance I would say a NASDAQ listing would bring more benefits than it does problems - but tbf I am no expert.
@berm yes very surprised that Lindy didn't do interviews yesterday. Its a huge step forward for the company and you would think publicity of the deal would important - unless of course other deals are already lined up ;-)
You didn't get back to me on the US listing point yesterday. I would have thought with money in the bank and more coming, now would be a good time to trade on a market that isn't the wild west.
(all in my humble opinion..)
comparatively speaking, Scancell don't spend a great deal of money compared to the pipeline they have and continue to add to. This deal today represent a small fraction of that pipeline, yet the upfront payments and near term targets (as well as cash at hand) will *likely finance Scancell for the medium term. As this ONE MaB progresses through development, ongoing payments escalate. This single deal has secured the financial future of Scancell with hardly any of the pipeline lost. This massively de-risks the long term investment.
Furthermore this puts to sleep the notion that Scancell are unable to deliver a commercial deal, or get full value for those deals.
This is looking increasingly like an "Arms Holding" scenario, and I would not be surprised to see more deals follow.
At least now we know why the change of Nomad.
My prediction - a U.S. listing soon.